Neue Kristalline Formen, Neue Pharmazeutische Zusammensetzung und Dosierschema eines Dipep-Tidylpeptidase-I-Hemmers zur Behandlung von Patienten mit Bronchiektasis oder Anderen Dpp-I-Vermittelten Erkrankungen
EP4768017
1. Juli 2026
Anmelder: Boehringer Ingelheim International GmbH 🇩🇪
Details
- Veröffentlichungs-Nr.
- EP4768017
- Anmeldetag
- 25. August 2025
- Veröffentlichung
- 1. Juli 2026
- Rechtsraum
- EP
- IPC
- A61K9/00
Abstract
The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and/or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and/or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.
Anmelder
- Firma
- Boehringer Ingelheim International GmbH
- Land
- 🇩🇪 Deutschland